Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia

W.-H. Yan a, *, A. Lin a, b, B.-G. Chen a, W.-D. Luo c, M.-Z. Dai a, X.-J. Chen a, H.-H. Xu a, B.-L. Li a

a Medical Research Center, Taizhou Hospital of Zhejiang province, Wenzhou Medical College, Linhai, Zhejiang, People’s Republic of China
b Human Tissue Bank, Taizhou Hospital of Zhejiang province, Wenzhou Medical College, Linhai, Zhejiang, People’s Republic of China
c Department of Hematology, Taizhou Hospital of Zhejiang province, Wenzhou Medical College, Linhai, Zhejiang, People’s Republic of China

Received: July 12, 2007; Accepted: September 21, 2007

Abstract

Human leukocyte antigen-G (HLA-G) molecule exerts multiple immunoregulatory functions that have been suggested to contribute to the immune evasion of tumour cells. Studies on HLA-G expression in malignant haematopoietic diseases are controversial, and the functions of HLA-G on this context are limited. In the current study, HLA-G expression was analysed in different types of patients: de novo acute myeloid leukaemia (AML, n = 54), B cell acute lymphoblastic leukaemia (B-ALL, n = 13), chronic myeloid leukaemia (CML, n = 9) and myelodysplastic syndrome (MDS, n = 11). HLA-G expression was observed in 18.5% cases of AML, 22.2% in CML and 18.2% in MDS, but not in B-ALL patients. In AML, HLA-G-positive patients had a significant higher bone marrow leukaemic blast cell percentage when compared with that of HLA-G-negative patients (P < 0.01). Total T-cell percentage was dramatically decreased in HLA-G-positive patients (P < 0.05). Cytogenetic karyotyping results showed that all HLA-G-positive AML patients (n = 5) were cytogenetically abnormal, which was markedly different from that of HLA-G-negative patients (P < 0.01). Ex vivo cytotoxicity analysis revealed that HLA-G expression in AML leukaemic cells could directly inhibit NK cell cytolysis (P < 0.01). These findings indicated that HLA-G expression in AML is of unfavourable clinical implications, and that HLA-G could be a potential target for therapy.

Keywords: HLA-G • acute myeloid leukaemia • NK cell • cytogenetics

Introduction

The expression of non-classical HLA class I molecule HLA-G was initially reported to be restricted to extra-villous cytotrophoblast and confers protection to foetus from maternal semi-allograft immune responses [1, 2]. HLA-G features low level of allelic polymorphisms and encodes seven protein isoforms generated by alternative splicing of its primary mRNA [3]. Extensive studies have been carried out on its functions in foetal-maternal immune maintenance. Studies suggested that HLA-G serves as a protection factor for foetus from maternal semi-allorecognition by the ability of HLA-G to modulate the functions of immune-competent cells, such as natural killer (NK)
cells, T lymphocytes and antigen-presenting cells [4]. HLA-G functioned as an immunotolerant that is involved in its interaction with diverse receptors, such as the immunoglobulin-like transcript 2 (ILT2), ILT4 and killer immunoglobulin-like receptor 2DL4 (KIR2DL4) expressed on these immune cells [5–8].

Other than extra-villous cytotrophoblasts, distribution of HLA-G expression recently has been found to be much broader than originally reported. An increasing number of studies addressed that HLA-G expression was observed in various malignancies, such as colorectal cancer, retinoblastoma, ovarian carcinoma, breast carcinoma, haematopoietic tumours, renal cell carcinoma, melanoma and lung cancer [9–17]. Few studies had been carried out for HLA-G antigen expression in malignant haematopoietic cells. However, data were controversial, and the functional roles of HLA-G in these diseases were limited [18–20].

In an effort to gain further insight into the role of HLA-G in malignant haematologic diseases, HLA-G cell surface expression was measured in bone marrow leukaemic blast cells from 87 malignant haematopoietic cells isolated from AML patients was performed ex vivo.

### Materials and methods

#### Patients

Eighty-seven patients with malignant haematopoietic diseases treated at the Department of Hematology, Wenzhou Medical College-affiliated Taizhou Hospital of Zhejiang Province were included in this retrospective study (between March 2006 and June 2007). Bone marrow samples were taken for diagnostic purposes, and surplus material was used in this study with informed consent of each patient according to institutional guidelines. Patient diagnosis was subclassified by morphological and by immunophenotyping. Patients with AML, CML, B-ALL or MDS at the time of diagnosis were characterized in Table 1.

The diagnosis was based on standard cytological criteria according to the French–American–British (FAB) classification. Fifty-four patients with AML, 9 patients with CML, 13 patients with B-ALL and 11 patients with MDS were enrolled in the study, respectively. Mononuclear cell isolation from bone marrow was performed with standard Ficoll-Paque (Sigma, Steinheim, Germany) density-gradient centrifugation method. Mononuclear cells from HLA-G negative (n = 11) and HLA-G strong positive samples (n = 3) were isolated and enriched by CD34 microbeads (Miltenyi Biotec, Auburn, CA, USA) according to the manufacturer's instructions for NK cell cytotoxicity analysis.

#### Cytogenetic analysis

Cytogenetic analysis of 21 cases from AML was performed using standard G-band karyotyping techniques. After bone marrow cells were processed using a short-term culture (24 hrs), 10 banded metaphases were analysed. Results were described according to the International System for Human Cytogenetic Nomenclature [21].

#### Flow cytometry

Bone marrow mononuclear cells were separated from freshly drawn anti-coagulated by Ficoll-Paque density-gradient centrifugation. Blasts were identified by CD45 dim/low side scatter characteristics according to Lacombe et al. [22]. A peridinin chlorophyll protein (PerCP)-labelled anti-CD45 antibody (BD, San Jose, CA, USA) was used to differentiate leukaemic cells from normal lymphocytes in

| Diagnosis   | No. | Sex (M/F) | Age (y) * | No. of HLA-Gpos patients (%) |
|-------------|-----|-----------|-----------|------------------------------|
| All patients| 87  | 46/41     | 50.3 ± 19.3 | 14 (16.1)                   |
| AML         | 54  | 28/26     | 50 ± 18.2  | 10 (18.5)                    |
| AML-M1      | 1   | 0/1       | 70         | 1 (100)                      |
| AML-M2      | 20  | 12/8      | 50.7 ± 20  | 4 (20.0)                     |
| AML-M3      | 14  | 6/8       | 44.3 ± 16.7| 2 (14.3)                     |
| AML-M4      | 9   | 4/5       | 57.3 ± 17.7| 0 (0)                        |
| AML-M5      | 11  | 6/5       | 48.9 ± 19.6| 3 (27.3)                     |
| B-ALL       | 13  | 5/8       | 43.7 ± 24.5| 0 (0)                        |
| CML         | 9   | 5/4       | 52.0 ± 19.7| 2 (22.2)                     |
| MDS         | 11  | 8/3       | 58.4 ± 18.4| 2 (18.2)                     |
| MDS-RA      | 6   | 3/3       | 53.2 ± 20.2| 0 (0)                        |
| MDS-RAEB    | 2   | 3/0       | 66 ± 8.5   | 0 (0)                        |
| MDS-RAEBT   | 3   | 3/0       | 63 ± 6.6   | 2 (66.7)                     |

*Age (year) was presented as mean ± standard deviation.

HLA-Gpos indicates HLA-G-positive patients.

© 2008 The Authors

Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
each case. HLA-G expression on leukaemic blast cells, which were differentiated from normal lymphocytes by CD45 dim/low side scatter fluorescence, was evaluated. 1 × 10⁶ mononuclear cells were incubated in 200 µL PBS at room temperature for 30 min. in the dark with 10 µL (1 mg/ml) fluorescein isothiocyanate (FITC)-conjugated antihuman HLA-G-specific monoclonal antibody MEM/G9 (IgG1, Serotec, Oxford, UK), and an isotype IgG was added as negative control (BD). After two washing steps with PBS, HLA-G expression was quantified by flow cytometry (FACSCalibur, BD). Ten thousand cells were studied for each analysis. Data were acquired and analysed using CellQuest software (BD).

Cytotoxicity analysis and HLA-G-specific mAb 87G blocking assay

Cytotoxicity analysis was performed using CytoTox96® Non- Radioactive Cytotoxicity Assay Kit (Promega, Madison, WI, USA). Effector NK-92 cells (ATCC, MD, USA) were cultured in alpha minimum essential (α-MEM) media without ribonucleosides and deoxyribonucleosides (Gibco BRL, Grand Island, NY, USA) supplemented with 12.5% heat-inactivated foetal calf serum (FCS) (Gibco BRL), 12.5% horse serum, 0.2 mM inositol, 0.1 mM 2-mercaptoethanol, 0.02 mM folic acid and 200 U/ml of rIL-2 (Bioscience, NY, USA) on the day before assay. Effector/target (E:T) ratio was optimized. During cytolysis assay, effector NK-92 cells were mixed with 1 × 10⁴ CD34-enriched blast target cells at a 20:1 E:T ratio in V-bottom 96-well plates (Costar, Cambridge, MA, USA) as protocol instructed. For the cytotoxicity experiments with an HLA-G-specific mAb 87G (gifted by Dr. Geraghty, Fred Hutchinson Cancer Research Center, Seattle, WA, USA) blockade, targets were pre-incubated with 5 µg/ml and 10 µg/ml 87G, respectively, for 30 min. before the effector NK-92 cells were added. Isotype IgG was added as an internal control. Target cell spontaneous release and maximal release of lactic dehydrogenase (LDH) and the effector cell spontaneous release of LDH were determined by incubating these cells in medium alone. Each assay was performed in quadruplicate, and the results are expressed as percentages of lysis ± S.D. The percentage of specific lysis was determined as follows:

(Experimental Release – Effector Spontaneous Release – Target Spontaneous Release)/(Target Maximum Release – Target Spontaneous Release) x 100.

Statistical analysis

Comparison of clinical or laboratory parameters was performed using the nonparametric Mann–Whitney U test for continuous variables and the χ² test for categoric data.
found for the percentage of B lymphocytes and NK cells in all patients studied (Table 2).

**HLA-G expression and the bone marrow cytogenetic karyotype**

Twenty-one AML samples (5 for HLA-G-positive and 16 for HLA-G-negative) were available for both the HLA-G expression measurement and the cytogenetic karyotyping. All five patients with HLA-G-positive showed cytogenetic karyotype abnormality, including two cases with t(15;17); two cases t(8;21) and 1 case with t(9;11), respectively, while 6 out of 16 HLA-G-negative patients are with cytogenetic karyotype abnormality, including two cases with t(7;11); two cases t(15;17), one case with t(6;9) and one case with +8, +8, +15, respectively. When compared, a significant difference was obtained (P < 0.01) (Table 3).
HLA-G expression and NK cytolysis against AML leukaemic blasts

HLA-G expression on tumour cells has been supposed to be an important way for malignant cells escaping from host immunosurveillance. We then investigated whether HLA-G protein expression in AML leukaemic cells could be associated with a decreased susceptibility to NK cytolysis. For this purpose, the IL-2-dependent leukaemic cell line NK-92 was used as a model of the NK effector cells. The cell line NK-92 was proved to be an excellent model system to study NK cell biology and KIR functions for its strong target cell cytolysis and well-defined cell surface markers, such as receptors ILT2 and KIR2DL4, which were involved in HLA-G-specific recognition [23, 24]. To test whether HLA-G expression on leukaemic cells from AML could directly exert an inhibition effect on NK cell cytolysis, blockade experiments with the HLA-G-specific mAb 87G were performed, which could exclude the involvement of other HLA molecules present on cells in the inhibition of NK-92 cytolysis. In this ex vivo study, no markedly different cytolysis was observed for the HLA-G-negative leukaemic cells when HLA-G was blocked. However, for the HLA-G-positive leukaemic cells, data showed that the NK cell lysis could be dramatically enhanced in a antibody dose-dependent manner when the cell surface HLA-G was blocked (Fig. 3), suggesting that HLA-G expression could directly protect AML leukaemic cells from NK-92 cell cytolysis.

Discussion

HLA-G could inhibit function(s) of immune effector cells through binding to diverse types of receptors, such as ILT2, ILT4 and KIR2DL4 [25]. Although its initial significance had been established in foetal–maternal immunotolerance, HLA-G has been suggested to provide tumour cells with an effective pathway to escape from anti-tumour immune responses [26–28]. In this context, Paul et al. [29] have described for the
first time that expression of HLA-G was found in solid tumours, and recently HLA-G expression has been observed in various tumours, including ovarian cancer, lung cancer, colon cancer, melanoma, breast cancer and renal cancer [30].

Few studies had been performed on HLA-G expression in different types of leukaemia patients, however, and data are limited and conclusions remain controversial. A group of previous studies addressed that no cell surface HLA-G was expressed in various types of haematopoietic diseases, such as AML, ALL, CLL and CML [19, 20, 31]. In contrast to these previous studies, a recent report by Nuckel et al. [18] concluded that all 47 cases of B-CLL samples express cell surface HLA-G antigen in a variable proportion of leukaemic tumour cells.

Methodology difference such as indirect immunofluorescence binding with the 87G antibody or direct immunofluorescence binding with the MEM/G9 antibody may partially address this controversy.

In the current study, cell surface HLA-G expression varies from 18.5% in AML, 22.2% in CML and 18.2% in MDS patients, respectively. However, no HLA-G expression was detected in B-ALL patients. A recent study by Gros et al. [32] showed that soluble HLA-G protein seems to be increased during acute leukaemia, especially in subtypes of AML-M4 and AML-M5, as well as in both B- and T-ALL patients. In our study, 3 out of 11 cases of AML-M5 patients were HLA-G-positive, but not detected in both AML-M4 and B-ALL patients. These data are consistent with the point that soluble HLA-G protein seems to be

---

**Table 3 HLA-G expression status and cytogenetic karyotype**

| Patient no. | Diagnosis | Sex | Age | HLA-G status | Karyotype                      | P*     |
|-------------|-----------|-----|-----|--------------|--------------------------------|--------|
| 1           | AML-M2    | F   | 75  | Positive     | 46XX, t(15;17)(q22;q21)        | <0.01  |
| 2           | AML-M5    | M   | 39  | Positive     | 46XY, t(9;11)(p11;p13)         |        |
| 3           | AML-M2    | F   | 40  | Positive     | 46XX, t(8;21)(q22;q22)         |        |
| 4           | AML-M3    | M   | 19  | Positive     | 46XY, t(15;17)(q22;q21)        |        |
| 5           | AML-M2    | M   | 75  | Positive     | 46XY, t(8;21)(q22;q22)         |        |
| 6           | AML-M2a   | M   | 59  | Negative     | 46XY, t(7;11)(p15;p15)         |        |
| 7           | AML-M2a   | M   | 52  | Negative     | 46XY, t(7;11)(p11;p13)         |        |
| 8           | AML-M4    | M   | 27  | Negative     | 46XY, t(6;9)(p23;q34)          |        |
| 9           | AML-M3    | F   | 53  | Negative     | 46XX, t(15;17)(q22;q11)        |        |
| 10          | AML-M3    | M   | 62  | Negative     | 46XY, t(15;17)(q22;q11)        |        |
| 11          | AML-M5b   | M   | 83  | Negative     | 49XY, +8, +8, +15              |        |
| 12          | AML-M5    | M   | 36  | Negative     | 46XY                           |        |
| 13          | AML-M3    | M   | 28  | Negative     | 46XY                           |        |
| 14          | AML-M3    | M   | 52  | Negative     | 46XY                           |        |
| 15          | AML-M2    | M   | 15  | Negative     | 46XY                           |        |
| 16          | AML-M2    | M   | 59  | Negative     | 46XY                           |        |
| 17          | AML-M2    | M   | 37  | Negative     | 46XY                           |        |
| 18          | AML-M5    | F   | 24  | Negative     | 46XX                           |        |
| 19          | AML-M3    | F   | 16  | Negative     | 46XX                           |        |
| 20          | AML-M2    | F   | 27  | Negative     | 46XX                           |        |
| 21          | AML-M2    | F   | 39  | Negative     | 46XX                           |        |

* Comparison between the HLA-G-positive and HLA-G-negative patients using the chi-square test.
Fig. 3 Cytotoxicity of NK cell against leukaemic cells isolated from AML patients and restored with an HLA-G-specific mAb 87G. Results were shown for 5-hr cytotoxicity assay using CD34-enriched leukaemic blasts isolated from different AML patients as the targets with an E:T ratio at 20:1. Experiments were performed in quadruplicate and the results were expressed as percentage of specific lysis ± S.D. (A) A PerCP-labelled anti-CD45 antibody was used to gate blasts that were characterized by CD45 dim/low side scatter (SSC) (upper panel). HLA-G-specific mAb FITC-labelled MEM-G/09 was used to measure HLA-G expression on the gated CD45 dim/low cells (low panel). (B) Cytotoxicity of NK cell against leukaemic cells isolated from AML patients and restored with an HLA-G-specific mAb 87G. For the blockade experiments, target cells were pre-incubated with 5 and 10 µg/ml 87G or an isotype-matched IgG as an internal control, respectively. For HLA-G-negative patients no. 1 (n = 11). * P < 0.05, ** P < 0.01.
more frequently expressed than membrane-bound HLA-G molecules in haematologic malignancies, such as lymphoproliferative disorders [33].

HLA-G molecules possess potent immune-suppressive properties by inhibition of NK cell functions and proliferation of CD4+ T lymphocytes, and by the induction of CD8+ T lymphocytes apoptosis and CD4+ T lymphocytes anergy [34–36], and by trogocytosis, HLA-G could lead to instantly generate T lymphocytes from effectors to regulatory cells [37]. HLA-G expression in CLL patients was found to be associated with both humoral and cellular immunosuppression [18]. In this study, the total T-cell percentage was dramatically lower in HLA-G-positive AML patients when compared with that in the HLA-G-negative group, while no such significance was found for both B lymphocytes and NK cells. Ex vivo cytotoxicity analysis in our study showed that HLA-G expressing in AML blasts could directly inhibit NK cell cytolyis, which could be restored by blockade of HLA-G with the HLA-G-conformational specific mAb 87G. However, whether functionality of NK cells in AML patients is altered remains unknown. A previous study indicated that NK cytolytic function was impaired in MDS patients partly due to the reduced NK-activating receptors [38]. Apart from this, HLA-G expression could also up-regulate NK cell inhibitory receptors, such as ILT2, ILT3, ILT4 and KIR2DL4, which may take part in immune evasion mechanisms [39]. These data indicated that HLA-G expression in malignant cells may result in host immune suppression, thus favouring tumour cells escaping from anti-tumour immunosurveillance and immune responses.

In addition, HLA-G expression association with a significantly higher percentage of bone marrow blast in AML patients was observed. In the current study, 21 cases of AML patients were available with both HLA-G expression status and cytogenetic karyotyping performed. Unexpectedly, all the HLA-G-positive AML patients were cytogenetic abnormal. The frequency of cytogenetic abnormality was markedly different between the HLA-G-positive and HLA-G-negative AML patients. Be noted, four out of five HLA-G-positive patients were with ‘favourable’ karyotypes, such as t(15;17) and t(8;21) [40, 41]. However, clinical implications of these associations remain unknown, and a larger cohort trial is necessary to confirm this.

In summary, for the first time, we demonstrated that various proportion of leukaemic cells express cell surface HLA-G. HLA-G expression is correlated to a significantly lower total T lymphocyte percentage, rather higher percentage of leukaemic blast cells and cytogenetic abnormalities in AML patients. Furthermore, HLA-G expression could directly inhibit the NK cell cytolysis against the malignant cells. These findings indicated that HLA-G exerts unfavourable clinical roles in AML.

Acknowledgements

This work was supported by the grants from Natural Science Foundation of Zhejiang Province, China (Y205531, Y205575), from the Health Bureau of Zhejiang Province (2007A195) and a grant from Ministry of Personnel, China. We are grateful to Dr. Geraghty (Fred Hutchinson Cancer Research Center, Seattle, WA, USA) for generously providing us antibodies.

References

1. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science. 1990; 248: 220–3.
2. Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Dausset J, Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol. 2003; 81: 199–252.
3. Paul P, Cabestre FA, Ibrahim EC, Lefebvre S, Khalil-Daher I, Vazeux G, Quiles RM, Bermond F, Dausset J, Carosella ED. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum Immunol. 2000; 61: 1138–49.
4. Hunt JS, Petroff MG, McIntire RH, Ober C. HLA-G and immune tolerance in pregnancy. FASEB J. 2005; 19: 681–93.
5. Shiroishi M, Kuroki K, Rasubala L, Tsumoto K, Kumagai I, Kurimoto E, Kato K, Kohda D, Maenaka K. Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Proc Natl Acad Sci USA. 2006; 103: 16412–7.
6. Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med. 1999; 189: 1093–100.
7. Yan WH, Fan LA. Residues Met76 and Gln79 in HLA-G alpha1 domain involve in KIR2DL4 recognition. Cell Res. 2005; 15: 176–82.

8. Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, Braud VM, Allan DS, Makdzange A, Rowland-Jones S, Willcox B, Jones EY, van der Merwe PA, Kumagai I, Maenaka K. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci USA. 2003; 100: 8856–61.

9. Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol. 2007; 20: 375–83.

10. Adithi M, Kandalam M, Ramkumar HL, Subramanian A, Venkatesan N, Krishnakumar S. Retinoblastoma: expression of HLA-G. Ocul Immunol Inflamm. 2006; 14: 207–13.

11. Lin A, Yan WH, Xu HH, Gan MF, Cai JF, Zhu M, Zhou MY. HLA-G expression in human ovarian carcinoma counteracts NK cell function. Ann Oncol. 2007; 18: 1804–9.

12. Singer G, Rebmann V, Chen YC, Liu HT, Ali SZ, Reinsberg J, McMaster MT, Pfeiffer K, Chan DW, Wardemann E, Grosse-Wilde H, Cheng CC, Kurman R, Shih IeM. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res. 2003; 9: 4460–4.

13. Sebti Y, Le Friec G, Pangault C, Gros F, Drénou B, Guilloux V, Bernard M, Lamy T, Fauchet R, Amiot L. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol. 2003; 64: 1093–101.

14. Bukur J, Rebmann V, Grosse-Wilde H, Luboldt H, Ruebben H, Drexler I, Sutter G, Huber C, Seliger B. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res. 2003; 63: 4107–11.

15. Lefebvre S, Antoine M, Uzan S, McMaster M, Dausslet J, Carosella ED, Paul P. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol. 2002; 196: 266–74.

16. Urosevic M, Kurrer MO, Kamarashev J, Mueller B, Weder W, Burg G, Stahl RA, Dummer R, Trojan A. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol. 2001; 159: 817–24.

17. Paul P, Cabestré FA, Le Gal FA, Khalil-Daher I, Le Danff C, Schmid M, Mercier S, Avril MF, Dausslet J, Guillet JG, Carosella ED. Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies. Cancer Res. 1999; 59: 1954–60.

18. Nuckel H, Rebmann V, Durig J, Duhrsen U, Grosse-Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood. 2005; 105: 1694–8.

19. Polakova K, Krcova M, Kuba D, Russ G. Analysis of HLA-G expression in malignant hematopoietic cells from leukemia patients. Leuk Res. 2003; 27: 643–8.

20. Mizuno S, Emi N, Kasai M, Ishitani A, Saito H. Aberrant expression of HLA-G antigen in interferon gamma-stimulated acute myelogenous leukaemia. Br J Haematol. 2000; 111: 280–2.

21. Mitelman F. International system for human cytogenetic nomenclature. Basel: S. Karger; 1995.

22. Lacombe F, Durrieu F, Briaux A, Dumein P, Belloc F, Bascans E, Reiffers J, Boisseye MR, Bernard P. Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia. 1997; 11: 1878–86.

23. Maki G, Klingemann HG, Martinson JA, Tam YK. Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J Hematother Stem Cell Res. 2001; 10: 369–83.

24. Yan WH, Lin A, Chen BG, Zhou MY, Dai MZ, Chen XJ, Gan LH, Zhu M, Shi WW, Li BL. Possible roles of KIR2DL4 expression on uNK cells in human pregnancy. Am J Reprod Immunol. 2007; 57: 233–42.

25. Hofmeister W, Weiss EH. HLA-G modulates immune responses by diverse receptor interactions. Semin Cancer Biol. 2003; 13: 317–23.

26. Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res. 2005; 65: 10139–44.

27. Rouas-Freiss N, Moreau P, Menier C, Carosella ED. HLA-G in cancer: a way to turn off the immune system. Semin Cancer Biol. 2003; 13: 325–36.

28. Shih IeM. Application of human leukocyte antigen-g expression in the diagnosis of human cancer. Hum Immunol. 2007; 68: 272–6.

29. Paul P, Rouas-Freiss N, Khalili-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausslet J, Guillet JG, Carosella ED. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA. 1998; 95: 4510–5.

30. Tripathi P, Agrawal S. Non-classical HLA-G antigen and its role in the cancer progression. Cancer Invest. 2006; 24: 178–86.

31. Amiot L, Onno M, Drenou B, Monvoisin C, Fauchet R. HLA-G class I gene expression in normal and malignant hematopoietic cells. Hum Immunol. 1998; 59: 524–8.

32. Gros F, Sebti Y, de Guibert S, Branger B, Bernard M, Fauchet R, Amiot L. Soluble HLA-G molecules increase during acute leukemia, especially in subtypes...
affecting monocytic and lymphoid lineages. 38. Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, Zou J, Ku E, Zhong B, Boulware D, Moscinski L, Wei S, Djeu JY, List AF. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood. 2007; 109: 4816–24.

33. Sebti Y, Le Friec G, Pangault C, Gros F, Drénou B, Guilloux V, Bernard M, Lamy T, Fauchet R, Amiot L. Soluble HLA-G molecules are increased in lymphoproliferative disorders. Hum Immunol. 2003; 64: 1093–101.

34. LeMaoult J, Krawice-Radanne I, Dausset J, Carosella ED. HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. Proc Natl Acad Sci USA. 2004; 101: 7064–9.

35. Fourmel S, Aguerre-Girr M, Huc X, Lenfant F, Alam A, Toubert A, Bensussan A, Le Bouteiller P. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol. 2000; 164: 6100–4.

36. Rouas-Freiss N, Goncalves RM, Menier C, Dausset J, Carosella ED. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA. 1997; 94: 11520–5.

37. LeMaoult J, Caumartin J, Daouya M, Favier B, Le Rond S, Gonzalez A, Carosella ED. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood. 2007; 109: 2040–8.